coexisting IBD, the update includes a conditional recommendation for TNFi monoclonal antibodies over other biologics, rather than over only etanercept. Finally, the recommendation for use of TNFi in patients with active nonradiographic axial SpA was changed from conditional to strong. New questions on the treatment of patients with stable disease were addressed in this update. Discontinuation of biologics is not recommended due to the likelihood for symptom recurrence. If tapering is